Latest News
News Functions
Additional Functions
8 July 2024
APEIRON Biologics AG
APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million
26 April 2022
APEIRON Biologics AG
APEIRON shareholders approve new group structure geared towards enabling innovation and growth
12 October 2021
APEIRON Biologics AG
APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01
6 July 2021
APEIRON Biologics AG
APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401
1 June 2021
APEIRON Biologics AG
APEIRON Biologics Announces Changes to Management and Supervisory Boards
19 May 2021
APEIRON Biologics AG
APEIRON Biologics’ APN01 selected for large-scale US trial in COVID-19
12 March 2021
APEIRON Biologics AG
APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial
4 December 2020
APEIRON Biologics AG
APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01
9 November 2020
APEIRON Biologics AG
APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery
15 October 2020
APEIRON Biologics AG
APEIRON Biologics AG strengthens shareholder structure and Supervisory Board with international anchor investor
25 September 2020
APEIRON Biologics AG
THE LANCET publishes promising data of APEIRON’s APN01 (rhsACE2) to treat COVID-19 in named patient use
8 July 2020
APEIRON Biologics AG
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
3 June 2020
APEIRON Biologics AG
APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19
18 May 2020
APEIRON Biologics AG
APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01
2 April 2020
APEIRON Biologics AG
APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19
26 February 2020
APEIRON Biologics AG
APEIRON startet klinische Pilotstudie in China mit Medikamentenkandidat für Atemwegserkrankungen zur Behandlung der Coronavirus-Erkrankung COVID-19
APEIRON Biologics AG
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China
21 October 2019
APEIRON Biologics AG
APEIRON to present preclinical data at the 2019 AACR-NCI-EORTC Conference
19 September 2018
APEIRON Biologics AG
APEIRON Announces Collaboration with Lead Discovery Center GmbH
28 August 2018
APEIRON Biologics AG
APEIRON Expands Executive Board and Appoints Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)
17 July 2018
APEIRON Biologics AG
APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer
29 June 2018
APEIRON Biologics AG
APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor
30 May 2018
APEIRON Biologics AG
APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual Meeting
9 January 2014
APEIRON Biologics AG
APEIRON Biologics AG: Apeiron Signs Regional License Agreements for the Commercialization of its Neuroblastoma Therapy